SAB Biotherapeutics, Inc. Common Stock (NASDAQ: SABS) last traded at $2.98, up 3.11% on the session. The quote above updates while this page is open; the figures below are drawn from SAB Biotherapeutics, Inc. Common Stock’s own filings and are restated only when a new one is published.
SAB Biotherapeutics, Inc. Common Stock trades on NASDAQ under the ticker SABS. Its market capitalisation is $271.14 million.
Valuation measures for SAB Biotherapeutics, Inc. Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $271.14M |
|---|---|
| Enterprise value | $286.30M |
| Price / book | 1.26 |
| Beta | 1.17 |
Trailing-twelve-month figures tagged in SAB Biotherapeutics, Inc. Common Stock's XBRL filings with the SEC.
| Revenue (TTM) |
|---|
| $0.00 |
| Net income (TTM) | -$12.78M |
|---|
| Return on equity | -5.95% |
|---|
| Cash | $8.27M |
|---|
Range and volume for SABS over the past 52 weeks.
| 52-week high | $5.15 |
|---|---|
| 52-week low | $2.10 |
| Volume | 659.6K |
| Average volume | 500.2K |
| Previous close | $2.89 |
Invest a chosen dollar amount in SAB Biotherapeutics, Inc. Common Stock with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell SABS.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.